First-in-human phase Ib trial of M9241 (NHS-IL12) plus avelumab in patients with advanced solid tumors, including dose expansion in patients with advanced urothelial carcinoma von Strauss, Julius, Deville, Jean-Laurent, Sznol, Mario, Ravaud, Alain, Maruzzo, Marco, Pachynski, Russell K, Gourdin, Theodore S, Maio, Michele, Dirix, Luc, Schlom, Jeffrey, Donahue, Renee N, Tsai, Yo-Ting, Wang, XiaoZhe, Vugmeyster, Yulia, Beier, Frank, Seebeck, Joerg, Schroeder, Andreas, Chennoufi, Sarah, Gulley, James L

Volltext

265 Phase 1b study of avelumab + M9241 (NHS-IL12) in patients with advanced solid tumors: interim analysis results from a urothelial carcinoma (UC) dose-expansion cohort von Deville, Jean-Laurent, Ravaud, Alain, Maruzzo, Marco, Gourdin, Theodore, Maio, Michele, Dirix, Luc, Wang, XiaoZhe, Vugmeyster, Yulia, Beier, Frank, Seebeck, Jeorg, Chennoufi, Sarah, Gulley, James

Volltext

Hardware implementation of HEVC CABAC binarization/de-binarization von Menasri, Wahiba, Djabri, Manel, Chennoufi, Sarah, Skoudarli, Abdellah, Bouhedda, Mounir, Benzineb, Omar

Volltext

Phase 1, open-label, dose-escalation study of M3814 + avelumab ± radiotherapy (RT) in patients (pts) with advanced solid tumors von Bendell, Johanna C., Shafique, Michael Rahman, Perez, Bradford, Chennoufi, Sarah, Beier, Frank, Trang, Ky, Antonia, Scott Joseph

Volltext